🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

36 results for “Iovance Biotherapeutics B.V.” Clear

  1. Lifileucel plus Pembrolizumab

    Iovance Biotherapeutics B.V.

    Metastatic Melanoma

    phase 3 mab active

    1 trial

  2. MESNA, MESNA, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Teva 25 mg/ml concentraat voor oplossing voor injectie of infusie, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan 1000 mg milteliai injekciniam tirpalui, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cycloph

    Iovance Biotherapeutics B.V.

    Melanoma

    phase 3 small molecule active

    1 trial

  3. Aldesleukin

    Iovance Biotherapeutics B.V.

    Bone Sarcoma

    phase 2 mab active

    1 trial

  4. Autologous Tumor Infiltrating Lymphocytes MDA-TIL

    Iovance Biotherapeutics B.V.

    Malignant Solid Neoplasm

    phase 2 mab terminated

    1 trial

  5. Cyclophosphamide

    Iovance Biotherapeutics B.V.

    Metastatic Bladder Urothelial Carcinoma

    phase 2 small molecule terminated

    1 trial

  6. Cyclophosphamide

    Iovance Biotherapeutics B.V.

    Clinical Stage IV Cutaneous Melanoma AJCC v8

    phase 2 small molecule completed

    1 trial

  7. E7 TCR-T cells

    Iovance Biotherapeutics B.V.

    Cervical Cancer

    phase 2 mab active

    1 trial

  8. E7 TCR-T cells

    Iovance Biotherapeutics B.V.

    HPV-Associated Cervical Carcinoma

    phase 2 mab active

    1 trial

  9. FLUDARABINE PHOSPHATE, ALDESLEUKIN, LN-145, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE

    Iovance Biotherapeutics B.V.

    Recurrent, metastatic, or persistent Cervical Carcinoma

    phase 2 small molecule active

    1 trial

  10. Fludarabine Teva 25 mg/ml solution à diluer pour injection ou perfusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, LN-145, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cyclophosphamide Injection 1 g., Fludarabine 50mg Powder For Solution For Injection Or Infusion, Endoxan, Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор, Fludarabinefosfaat – PCH 25 mg/ml, concentraat voor oplossing voor injectie/infusie, FLUDARAB

    Iovance Biotherapeutics B.V.

    Metastatic Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  11. IOV-3001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  12. IOV-4001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  13. LN-145

    Iovance Biotherapeutics B.V.

    Squamous Cell Carcinoma of the Head and Neck

    phase 2 mab completed

    1 trial

  14. LN-145

    Iovance Biotherapeutics B.V.

    Non Small Cell Lung Cancer

    phase 2 mab terminated

    1 trial

  15. LN-145

    Iovance Biotherapeutics B.V.

    Metastatic Non Small Cell Lung Cancer

    phase 2 mab active

    1 trial

  16. LN-145

    Iovance Biotherapeutics B.V.

    Cutaneous Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  17. LN-145

    Iovance Biotherapeutics B.V.

    Cervical Carcinoma

    phase 2 mab terminated

    1 trial

  18. LN-145, ALDESLEUKIN, Lifileucel, Fludarabine 50mg Powder For Solution For Injection Or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, NIVOLUMAB, Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Accord 25 mg/ml koncentratas injekciniam ar infuziniam tirpalui, IPILIMUMAB, Cyclophosphamide Injection 1 g.

    Iovance Biotherapeutics B.V.

    Neoplasm

    phase 2 small molecule active

    1 trial

  19. Lifileucel

    Iovance Biotherapeutics B.V.

    Endometrial Cancer

    phase 2 mab active

    1 trial

  20. Lifileucel

    Iovance Biotherapeutics B.V.

    Melanoma (Skin Cancer)

    phase 2 mab active

    1 trial

  21. Lifileucel

    Iovance Biotherapeutics B.V.

    Metastatic Melanoma

    phase 2 mab completed

    2 trials

  22. PROLEUKIN® 18 x 106 IU Powder for solution for injection or infusion, Lifileucel, Cyclophosphamide Injection 1 g, FLUDARABINE

    Iovance Biotherapeutics B.V.

    Previously treated advanced melanoma

    phase 2 small molecule active

    1 trial

  23. Tumor infiltrating lymphocytes (TIL) LN-145

    Iovance Biotherapeutics B.V.

    Metastatic Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  24. Cyclophosphamide

    Iovance Biotherapeutics B.V.

    Locally Advanced Melanoma

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources